iih glp 1 Beyond weight loss: a case study and narrative review of the potential role of glucagon-like peptide-1 receptor agonists for the treatment of idiopathic intracranial hypertension - Paulo Exenatide (a GLP-1 receptor agonist)
Description
10.1021/acssensors.9b01414 [DOI] [PubMed] [Google Scholar] Onaran, H
39,95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others References Drucker, D
DURATION diabetes therapy utilization: researching changes in A1C, weight and other factors through intervention with exenatide QW (extended-release exenatide, 2 mg, once weekly), EQW exenatide QW, HDL-C high density lipoprotein cholesterol, GLP-1 RA glucagon-like peptide-1 receptor agonist, LDL-C low density lipoprotein cholesterol, RCTs randomised controlled trials, T2DM type 2 diabetes mellitus, TZD thiazolidinediones Table 15
AOD-9604 runs in 12-week cycles
Always verify the patient's specific formulary and tier placement before prescribing
